Exosome RNA Exosome RNA Research & Industry News
Delivering RNA into cells safely and efficiently is one of the biggest challenges in developing modern therapies like RNA vaccines and gene therapies. Scientists are exploring alternatives to viruses, which are often used as delivery tools but can trigger immune responses or raise safety concerns. One promising option is extracellular vesicles (EVs), tiny particles naturally released by cells that can carry biological cargo such as RNA and proteins.
In recent work at Harvard Medical School, researchers focused on improving a specialized type of engineered EV called enveloped protein nanocages (EPNs). These structures can be designed to package and deliver RNA into target cells, especially when combined with a viral fusion protein like VSV-G, which helps the vesicles enter cells more effectively.
Strategy of EV production and their titration
(A) Biological titration assay workflow. 293 T producer cells are transfected with EV packaging-cargo construct (EVPCs) and VSV-G, then cultured in the presence of the HCV NS3/4A inhibitor grazoprevir (GZR). Cell-free supernatant is serially diluted 10-fold; 10 µL of each dilution is added to BHK-21 recipient cells (transiently transfected with pCALSL-DsRed) in 500 µL of medium (first well, 10 µL undiluted supernatant). After 4 d, DsRed+ cells are counted by inverted fluorescence microscopy. (B) EVPC design. All variants contain the PLCδ1-PH membrane-targeting domain, the I3-01 self-assembling nanocage (with Met3 in EVPC-1 to EVPC-4; reverted to Ile in EVPC-5), HCV NS3/4A protease, and a λN peptide (ΔMet1) for BoxB-mediated mRNA tethering; Cre-P2A-EGFP is linked downstream via T2A, and a 14×BoxB array is placed in the 3′UTR. ESCRT-recruitment modules are either HIV-1 Gag p6 or the CEP55 EABR, positioned internally (between PH and I3-01) or at the C terminus. (C) Schematic of EVs produced by coexpression of EVPC-5 and VSV-G plasmids, with the functional titers plotted (D) as DU/mL (mean ± SEM, n = 8). (E) Test of linearity of titration method: adjacent wells had serial 10-fold dilutions of an EV supernatant added, with counts of DsRed+ cells carried out 4 d later. The fold change among wells was measured (n = 8) and the P-value was calculated using a one-sample t test against a value of 10.
One of the key challenges in advancing these systems has been the lack of reliable ways to measure how well individual EVs perform. To solve this, the team developed a biological titration assay, similar to methods used to measure infectious virus particles. This allowed them to evaluate EV performance at a much more precise level and systematically improve their design.
Using this new assay, the researchers built a modular EV platform made mostly from human-derived proteins. By combining components from proteins such as epsin 1, CLYBL, and CEP55, they engineered EVs that could efficiently package and deliver RNA. Importantly, they also included a short peptide sequence to help load RNA into the vesicles.
The result was a delivery system that performed at levels comparable to well-established viral tools like lentiviral vectors, but with a major advantage: reduced immunogenicity. Because these EVs are largely built from human proteins, they are less likely to trigger unwanted immune responses, making them especially attractive for therapeutic use.
Overall, this work highlights how engineered extracellular vesicles can be refined into powerful, safer alternatives to viral delivery systems. As RNA-based therapies continue to expand, platforms like these could play a critical role in improving both effectiveness and patient safety.
